UNLABELLED: The mechanisms associated with hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) remain elusive, and there are currently no well-established animal models for studying this disease. Using the Sleeping Beauty transposon as a delivery system, we introduced an oncogenic component of HBV, the hepatitis B virus X (HBx) gene, into the livers of fumarylacetoacetate hydrolase (Fah) mutant mice via hydrodynamic tail vein injections. Coexpression of Fah complementary DNA from the transposon vector allowed for the selective repopulation of genetically corrected hepatocytes in Fah mutant mice. The process of hydrodynamic delivery induced liver inflammation, and the subsequent selective repopulation of hepatocytes carrying the transgene(s) could provide useful genetic information about the mechanisms of HBV-induced hyperplasia. Short hairpin RNA directed against transformation-related protein 53 (shp53) or other tumor suppressor genes and oncogenes [e.g., constitutively active neuroblastoma RAS viral (v-ras) oncogene homolog with Gly12Val substitution (NRAS(G12V) )] could also be codelivered with HBx by this system so that we could determine whether oncogenic cooperation existed. We found that the expression of HBx induced the activation of β-catenin expression in hydrodynamically injected livers, and this indicated its association with the Wnt signaling pathway in HBV-induced hyperplasia. HBx coinjected with shp53 accelerated the formation of liver hyperplasia in these mice. As expected, constitutively active NRAS(G12V) alone was sufficient to induce liver hyperplasia, and its tumorigenicity was augmented when it was coinjected with shp53. Interestingly, HBx did not seem to cooperate with constitutively active NRAS(G12V) in driving liver tumorigenesis. CONCLUSION: This system can be used as a model for studying the various genetic contributions of HBV to liver hyperplasia and finally HCC in an in vivo system.
UNLABELLED: The mechanisms associated with hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) remain elusive, and there are currently no well-established animal models for studying this disease. Using the Sleeping Beauty transposon as a delivery system, we introduced an oncogenic component of HBV, the hepatitis B virus X (HBx) gene, into the livers of fumarylacetoacetate hydrolase (Fah) mutant mice via hydrodynamic tail vein injections. Coexpression of Fah complementary DNA from the transposon vector allowed for the selective repopulation of genetically corrected hepatocytes in Fah mutant mice. The process of hydrodynamic delivery induced liver inflammation, and the subsequent selective repopulation of hepatocytes carrying the transgene(s) could provide useful genetic information about the mechanisms of HBV-induced hyperplasia. Short hairpin RNA directed against transformation-related protein 53 (shp53) or other tumor suppressor genes and oncogenes [e.g., constitutively active neuroblastoma RAS viral (v-ras) oncogene homolog with Gly12Val substitution (NRAS(G12V) )] could also be codelivered with HBx by this system so that we could determine whether oncogenic cooperation existed. We found that the expression of HBx induced the activation of β-catenin expression in hydrodynamically injected livers, and this indicated its association with the Wnt signaling pathway in HBV-induced hyperplasia. HBx coinjected with shp53 accelerated the formation of liver hyperplasia in these mice. As expected, constitutively active NRAS(G12V) alone was sufficient to induce liver hyperplasia, and its tumorigenicity was augmented when it was coinjected with shp53. Interestingly, HBx did not seem to cooperate with constitutively active NRAS(G12V) in driving liver tumorigenesis. CONCLUSION: This system can be used as a model for studying the various genetic contributions of HBV to liver hyperplasia and finally HCC in an in vivo system.
Authors: Ross A Dickins; Michael T Hemann; Jack T Zilfou; David R Simpson; Ingrid Ibarra; Gregory J Hannon; Scott W Lowe Journal: Nat Genet Date: 2005-10-02 Impact factor: 38.330
Authors: X W Wang; M K Gibson; W Vermeulen; H Yeh; K Forrester; H W Stürzbecher; J H Hoeijmakers; C C Harris Journal: Cancer Res Date: 1995-12-15 Impact factor: 12.701
Authors: Yujin Hoshida; Sebastian M B Nijman; Masahiro Kobayashi; Jennifer A Chan; Jean-Philippe Brunet; Derek Y Chiang; Augusto Villanueva; Philippa Newell; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Stacey Gabriel; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub Journal: Cancer Res Date: 2009-09-01 Impact factor: 12.701
Authors: Justin R Prigge; James A Wiley; Emily A Talago; Elise M Young; Laura L Johns; Jean A Kundert; Katherine M Sonsteng; William P Halford; Mario R Capecchi; Edward E Schmidt Journal: Mamm Genome Date: 2013-09-11 Impact factor: 2.957
Authors: Amy P Chiu; Barbara R Tschida; Tung-Ting Sham; Lilian H Lo; Branden S Moriarity; Xiao-Xiao Li; Regina C Lo; David E Hinton; Dewi K Rowlands; Chi-On Chan; Daniel K W Mok; David A Largaespada; Nadia Warner; Vincent W Keng Journal: Mol Cancer Res Date: 2019-04-11 Impact factor: 5.852
Authors: Vincent W Keng; Daniela Sia; Aaron L Sarver; Barbara R Tschida; Danhua Fan; Clara Alsinet; Manel Solé; Wai L Lee; Timothy P Kuka; Branden S Moriarity; Augusto Villanueva; Adam J Dupuy; Jesse D Riordan; Jason B Bell; Kevin A T Silverstein; Josep M Llovet; David A Largaespada Journal: Hepatology Date: 2012-10-19 Impact factor: 17.425
Authors: Amy P Chiu; Barbara R Tschida; Lilian H Lo; Branden S Moriarity; Dewi K Rowlands; David A Largaespada; Vincent W Keng Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742